An investigation on behalf of current long term investors in American Renal Associates Holdings Inc (NYSE:ARA) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NYSE:ARA stockholders should contact the Shareholders Foundation.
San Diego, CA -- (ReleaseWire) -- 11/28/2017 -- An investigation was announced for investors in shares of American Renal Associates Holdings Inc (NYSE:ARA) concerning potential breaches of fiduciary duties by certain directors.
Investors who are current long term investors in American Renal Associates Holdings Inc (NYSE:ARA) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm for investors in NYSE:ARA stocks follows a lawsuit pending against American Renal Associates Holdings Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE:ARA stocks, concerns whether certain American Renal Associates Holdings Inc directors are liable in connection with the allegations made in that lawsuit.
The plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired American Renal securities pursuant and/or traceable to American Renal's false and misleading Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about April 21, 2016 (the "IPO" or the "Offering") and/or on the open market between April 21, 2016 and August 18, 2016, that the defendants violated Federal Securities Laws. The plaintiff claims that between Defendants made false and/or misleading statements and/or failed to disclose that American Renal Associates Holdings Inc was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act ("ACA") plans to obtain greater reimbursement for the Company's dialysis services, that the foregoing scheme was in violation of federal and state laws, and that as a result of the foregoing, American Renal Associates Holdings' public statements were materially false and misleading at all relevant times.
Those who purchased shares of American Renal Associates Holdings Inc (NYSE:ARA) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels